Genmab — April 2018

[E_L]

yes Polle, thank you. But normally it is only girls that tell me how good looking I am

[polle1]

[E_L]

the thing is, whenever the stock is trading this stupid i feel the need to check & search for what happened; i should know better after watching it for so long....but it is hard to resist...

[polle1]

I totally agree, I do exactly the same, and can't find anything negative. So, "same procedure as every time" : stay patient

[polle1]

Hvor blev tallene dog af idag ?

[E_L]

This old Ofa study was set to 'completed' (CHOP) With Ofatumumab in Patients With Richter's Syndrome (CHOP-OR) https://clinicaltrials.gov/ct2/show/NCT01171378?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F24%2F2018&rank=1

[E_L]

and this on has some results (still active) Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1) - https://clinicaltrials.gov/ct2/show/results/NCT00748189?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=04%2F24%2F2018&rank=4

[E_L]

and ASCO titles, have fun https://iplanner.asco.org/am2018/#/

[Bulder]

Det ser tyndt ud - kun opdateringer. BB2121 har en oral session.

[E_L]

yes, did not expect much though.

[E_L]

Poster on tisotumab in cervical cancer

[Bulder]

I don't think they have results on that yet.

[Bulder]

Dara har også fået en oral opfølgning på MMY1001 D-Kd

[E_L]

that looks the most interesting so far then?
(if no results on tisotumab; you are probable correct on that)

[Bulder]

Men ingen BMS-data på dara+nivo. Vi må vente til ESMO

[Solsen]

11 abstracts med dara

[Bulder]

Der kan muligvis være lidt nyt i opdateringen på sc dara i PAVO-studiet. Der var jo rygter fremme om at sc var mere effektiv end IV.

[Solsen]

CyborD og flere sc. Noget isatuximab etc. Flere interessante.

[Solsen]

Ja det ville være godt. Vi kan jo også få bekræftet Amyloidosis effekten ovenpå en konkurrents fald.

[Bulder]

Men mærkeligt nok ikke noget om dette studie https://www.clinicaltrials.gov/ct2/show/NCT02951819?term=daratumumab+cybord&rank=3 , der havde Primary Completion Date 8. marts.